J&J, Novartis Drugs to Face Colorado Board’s Payment Limits (1)

Top-selling arthritis and psoriasis drugs from Johnson & Johnson and Novartis AG are likely to see caps on what health plans in Colorado pay for the medications after votes Wednesday by the state’s drug pricing review board.

The Colorado Prescription Drug Affordability Board decided to pursue rulemaking to establish upper payment limits for J&J’s Stelara and Novartis’ Cosentyx. The move opens up the board to additional litigation as the panel battles a lawsuit from Amgen Inc. over the board’s February vote to develop a UPL for the autoimmune treatment Enbrel.

The board voted last month to declare Stelara and Cosentyx ...